Roles of endothelin ETA and ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 2, 2004, Pages 187-191

  Nishida, Masahiro ^a   Eshiro, Keiko ^a   Okada, Yuka ^a   Takaoka, Masanori ^a   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Endothelin 1; ETA receptor; ETB receptor; Monocrotaline; Pulmonary hypertension

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ATRASENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; MONOCROTALINE; PYRROLIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; HEART HYPERTROPHY; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE PRESSURE; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DIGESTIVE TRACT INTUBATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; HEART; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HISTOLOGY; LUNG; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TUNICA MEDIA; VASCULARIZATION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CARDIOMEGALY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEART; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; INJECTIONS, SUBCUTANEOUS; INTUBATION, GASTROINTESTINAL; LUNG; MALE; MONOCROTALINE; ORGAN SIZE; PULMONARY ARTERY; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; TIME FACTORS; TUNICA MEDIA; VENTRICULAR PRESSURE;

EID: 3242767660     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200408000-00007     Document Type: Article

References (28)

1. Michel RP, Langleben D, Dupuis J. The endothelin system in pulmonary hypertension. Can J Physiol Pharmacol. 2003;81:542-554.
2. Stewart DJ, Levy R, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464-469.
3. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
4. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
5. Frasch HF, Marshall C, Marshall BE. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol. 1999;276:L304-L310.
6. Miyauchi T, Yorikane R, Sakai S, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res. 1993;73:887-897.
7. A receptor blockade. Clin Sci. 2003;105:647-653.
8. A antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation. 2001;103:314-318.
9. Hill NS, Warburton RR, Pietras L, et al. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol. 1997;83:1209-1215.
10. A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol. 1994;266:H1327-H1331.
11. Sato K, Morio Y, Morris KG, et al. Mechanism of hypoxic pulmonary vasoconstriction involves ET (A) receptor-mediated inhibition of K (ATP) channel. Am J Physiol. 2000;278:L434-L442.
12. Ono S, Voelkel NF. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol. 1991;71:2483-2492.
13. Matsumura Y, Hashimoto N, Taira S, et al. Different contribution of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension. 1999; 33:759-765.
14. Okada M, Yamashita C, Okada M, et al. Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension. Circulation. 1995;92:114-119.
15. Okada M, Yamashita C, Okada M, et al. Endothelin receptor antagonists in a beagle model of pulmonary hypertension: Contribution to possible potential therapy? J Am Coll Cardiol. 1995;25:1213-1217.
16. Ivy DD, Parker TA, Abman AS. Prolonged endothelin B receptor blockade causes pulmonary hypertension in the ovine fetus. Am J Physiol. 2000;279:L758-L765.
17. Ivy DD, Parker TA, Ziegler JW, et al. Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Invest. 1997;99:1179-1186.
18. Ivy DD, Yanagisawa M, Gariepy CE, et al. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol. 2002;282:L703-L712.
19. B receptor in rats. Biochem Biophys Res Commun. 1994;199: 1461-1465.
20. B receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem. 1994;269: 21778-21785.
21. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol. 2001;281:F144-F150.
22. Matsumura Y, Kuro T, Kobayashi Y, et al. Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation. 2000;102:2765-2773.
23. A receptors. Am J Physiol. 2002;283:H1555-H1561.
24. Fukuroda T, Fujikawa T, Ozaki S, et al. Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol. 1994;113:336-338.
25. B blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol. 1995;269:L668-L672.
26. B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol. 1996;119:1125-1130.
27. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398-405.
28. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension. Chest. 2002;121:1860-1868.